Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Is Empagliflozin equivalent and/or synergistic with angiotensin-converting enzyme inhibition in the prevention of chemotherapy mediated cardiotoxicity?

EF 2023-24

Résumé
Breast cancer is a major health problem in Canada. Doxorubicin and Trastuzumab (DOX+TRZ) are two of the most common anti-cancer drugs used in the treatment of breast cancer. While these anti-cancer drugs improve overall survival in patients with breast cancer, they increase the risk of developing heart failure. About 1 in 4 women with breast cancer are at risk of developing heart failure due to DOX+TRZ, affecting over 8000 women in Canada every year. In the EMPACT-BC study, we will explore the role of a new medication Empagliflozin (EMPA) in the prevention of heart failure caused by DOX+TRZ. EMPA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently used as a novel anti-diabetic medication. Recent randomized controlled trials have demonstrated that SGLT2 inhibitors reduce the risk of heart failure associated hospitalization and mortality in patients with and without diabetes. Little is known, however, about whether SGLT2 inhibitors are cardioprotective in the setting of chemotherapy mediated cardiotoxicity. We will evaluate whether EMPA is equivalent and/or synergistic to standard pharmacological therapy using renin-angiotensin system (RAS) antagonists, namely perinodpril. We will study this drug in an animal model. Over 6 weeks, female mice will receive a combination of the drug EMPA with DOX+TRZ. We will image the hearts of the mice using ultrasound to explore the protective effects of EMPA on the heart's structure and function. Based on the information that we will find out in this basic science study, we plan to perform a clinical trial in the near future. We will study if EMPA can prevent heart failure in individuals receiving treatment for breast cancer. This innovative study will improve the quality of heart health in women with breast cancer.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506203
Name
Rozovsky Tim
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Is Empagliflozin equivalent and/or synergistic with angiotensin-converting enzyme inhibition in the prevention of chemotherapy mediated cardiotoxicity?
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ace Inhibition; Breast Cancer; Cardio-Oncology; Cardiotoxicity; Doxorubicin; Echocardiography; Empagliflozin; Heart Failure; Sglt2; Trastuzumab
Abstract
Breast cancer is a major health problem in Canada. Doxorubicin and Trastuzumab (DOX+TRZ) are two of the most common anti-cancer drugs used in the treatment of breast cancer. While these anti-cancer drugs improve overall survival in patients with breast cancer, they increase the risk of developing heart failure. About 1 in 4 women with breast cancer are at risk of developing heart failure due to DOX+TRZ, affecting over 8000 women in Canada every year. In the EMPACT-BC study, we will explore the role of a new medication Empagliflozin (EMPA) in the prevention of heart failure caused by DOX+TRZ. EMPA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently used as a novel anti-diabetic medication. Recent randomized controlled trials have demonstrated that SGLT2 inhibitors reduce the risk of heart failure associated hospitalization and mortality in patients with and without diabetes. Little is known, however, about whether SGLT2 inhibitors are cardioprotective in the setting of chemotherapy mediated cardiotoxicity. We will evaluate whether EMPA is equivalent and/or synergistic to standard pharmacological therapy using renin-angiotensin system (RAS) antagonists, namely perinodpril. We will study this drug in an animal model. Over 6 weeks, female mice will receive a combination of the drug EMPA with DOX+TRZ. We will image the hearts of the mice using ultrasound to explore the protective effects of EMPA on the heart's structure and function. Based on the information that we will find out in this basic science study, we plan to perform a clinical trial in the near future. We will study if EMPA can prevent heart failure in individuals receiving treatment for breast cancer. This innovative study will improve the quality of heart health in women with breast cancer.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rozovsky, Tim
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~